Premium
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
Author(s) -
Ahlskog J. Eric,
Uitti Ryan J.,
O'Connor Michael K.,
Maraganore Demetrius M.,
Matsumoto Joseph Y.,
Stark Kathy F.,
Turk Margaret F.,
Burnett Omer L.
Publication year - 1999
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y
Subject(s) - pergolide , putamen , dopamine transporter , dopamine , medicine , dopamine agonist , caudate nucleus , parkinson's disease , striatum , endocrinology , agonist , dopaminergic , disease , receptor
Single‐photon emission computed tomography (SPECT) imaging with the dopamine transporter ligand, [ 123 I] β‐CIT (2β‐carboxymethoxy‐3β‐[4‐iodophenyl] tropane), has been proposed as a means of measuring Parkinson's disease (PD) progression. To be useful in this role, however, [ 123 I] β‐CIT imaging should not be influenced by the medications used to treat PD, including the dopamine agonist drugs such as pergolide. We assessed the effect of adjunctive pergolide administration on [ 123 I] β‐CIT uptake in 12 patients with PD, who were being treated with levodopa, initiating pergolide therapy for motor fluctuations. Patients underwent [ 123 I] β‐CIT imaging at baseline, subsequently while on pergolide therapy (6 weeks), and again 4 weeks after pergolide wash‐out. Uptake in the striatum was averaged for the two sides and expressed as (striatum − occipital)/occipital, with similar calculations for putamen and caudate. Consistent with PD, the patients' mean striatal and putamen uptake ratios at baseline were significantly less (p <0.001) than the mean values from 26 normal control subjects of similar age. During pergolide treatment, the striatal and putamen [ 123 I] β‐CIT uptake ratios were each statistically similar to baseline, although there was a slight trend toward an increased striatal value (8% higher on pergolide; p = 0.105). Caudate [ 123 I] β‐CIT uptake was 11% higher on pergolide therapy (nominal p = 0.042, but not significant when adjusted for multiple comparisons: p = 0.126). After pergolide wash‐out, the striatal, putamen, and caudate uptake ratios did not differ from baseline. Therefore, we found that pergolide therapy did not significantly affect [ 123 I] β‐CIT SPECT imaging but we cannot exclude a small influence.